Mean ratings of interest in considering the use of incretin‐based anti‐obesity medications was 4.6 (SD = 1.3) on a 1–6 scale, suggesting a moderate‐to‐high overall interest. This evidence concerns the gene GCG and obesity due to melanocortin 4 receptor deficiency.